MedTrace Logo

A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022

NCT03563183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26976

Last updated 2020-04-30

Study results available
· View outcomes & findings →

Summary

As part of the ZOSTER-006 and ZOSTER-022 pivotal trials of the HZ/su vaccine, all study participants completed quality of life (QoL) questionnaires. The only questionnaires encoded into the data base were those from participants who developed a suspected shingles episode during the study.

The purpose of this study is to allow for the encoding and analysis of questionnaires for all subjects enrolled in ZOSTER-006 and ZOSTER-022. The aim is to assess the baseline frailty of subjects enrolled in these studies and to investigate whether this population is representative of the general population.

Conditions

  • Herpes Zoster

Interventions

OTHER

Encoding of data collected in Zoster 006 and Zoster 022 studies

Not applicable (disease epidemiology study)

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-05
Primary Completion
2019-04-30
Completion
2019-04-30
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • Canada
  • Czechia
  • Estonia
  • Finland
  • France
  • Germany
  • Hong Kong
  • Italy
  • Japan
  • Mexico
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03563183 on ClinicalTrials.gov